Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. - Wikidata - awgldk - TriplyDB

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

http://www.wikidata.org/entity/Q42221150

about

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies Ibrutinib (PCI-32765) in chronic lymphocytic leukemia Signal transduction in the chronic leukemias: implications for targeted therapies The tumor microenvironment shapes hallmarks of mature B-cell malignancies.Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.B-cell receptor signaling as a driver of lymphoma development and evolution.Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition.Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.Therapeutic advancement of chronic lymphocytic leukemia.Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.Ibrutinib: a paradigm shift in management of CLL.Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling Time-resolved luminescence detection of spleen tyrosine kinase activity through terbium sensitization Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.Targeted therapy in chronic lymphocytic leukemia: past, present, and future.Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.Targeting the B cell receptor pathway in chronic lymphocytic leukemia.Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.B cell receptor signaling in chronic lymphocytic leukemia.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.

P2860

Q26744277-D7E93E19-ECF6-4418-A120-5638FEFE22F7 Q26782633-EE39EF7E-C0A4-4F85-BCD3-6AE318DC99E0 Q26798062-E40489AD-AB32-4437-B632-669B4FC232E7 Q26822700-9DFD6C20-7E18-4FC5-B3C4-7FEF8AF752B5 Q26852328-18073CF7-37D4-479D-ABAB-543A13C8761D Q27026031-167E258C-CB36-4537-B155-166D0A7D3590 Q27687567-70D0AAE8-FDE0-48AB-A5ED-22E4215E6143 Q27853177-5C65B7E8-A015-44BF-B384-E8F3445162A8 Q28484839-624DD510-0568-49C1-972B-2CAF3EC3D646 Q30433183-EB2F997D-F11C-43DA-8088-3F9C54A7DA3B Q33578875-F4DA69BB-55F4-438E-9267-D59C11A37DEE Q34398579-B55E7CF2-FBEC-4603-85E9-F1F4B2080A69 Q35054626-89EF0555-ED60-4FAB-BDD4-7B7F9C591194 Q35061209-6D419455-F62D-4FCD-B755-4DE3E05EC78F Q35110849-ADB4055F-6916-409A-B9FA-CED4E0C322CF Q35140015-1B9AA72C-0DC2-4F82-9D46-5A333EB45D50 Q36236545-FEC12E76-77CC-49B1-8143-F136D8ACCAA2 Q36300303-9465A189-8C68-4C5E-837F-4259173C4630 Q36404778-F21AD668-63AF-47CD-980F-86DCB61DDEA6 Q36462375-1A193BDD-1494-41A4-99D0-6320CDE94F49 Q36573201-377E51F7-3CB6-4478-A571-1AA989445E9B Q36739295-28DF7A06-CBAC-486E-A4D3-D14FD664A072 Q36782109-C1B11C17-632A-4240-A5A2-AE359E25EF12 Q36784324-0437B321-4A46-4DE6-AB3A-E02184886FF4 Q36862781-FE5B502A-6E87-4136-830B-62FAA26BECD4 Q36870866-A50C5268-7CC7-4AA3-B56D-B1CF09A04AFD Q36931139-F8DF0DDE-A863-4B33-BE89-D349A98CF0D1 Q37205238-9C9E61B7-7EEE-4887-82DC-7186E4DFAF15 Q37430243-74199762-D83B-4B62-A995-F0AE32364F5E Q37576591-EF8F4B3E-E9FC-4999-A171-DC17054E7C50 Q37610087-7E1B2B09-8BC6-4A19-B069-3E1FE0E7FF85 Q37706530-75E72179-1193-44E8-9597-511BB5181404 Q38012179-C550724B-F222-4CBB-91BC-ED8900A67D21 Q38046045-3F15BCEA-F690-441F-BD60-58B70785D3F2 Q38069567-FBBEC39C-FC11-44F0-9F89-463FB151049D Q38101590-4D0B1EF4-6610-4383-B800-72AB99D91CDE Q38101683-E74F2EEC-B914-4354-B725-E0B0F88153E1 Q38124119-F46F44BC-7A78-4D23-9984-83A50E10FA7E Q38127513-3B8BBF63-E7DB-4EB0-84B3-77B939291D2B Q38150876-D245FC26-1446-496E-98D7-965A2D9C40A2

P2860

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

http://www.wikidata.org/entity/Q42221150

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Selective, novel spleen tyrosi ...... cell activation and migration.

@en

Selective, novel spleen tyrosi ...... cell activation and migration.

@nl

type

label

Selective, novel spleen tyrosi ...... cell activation and migration.

@en

Selective, novel spleen tyrosi ...... cell activation and migration.

@nl

prefLabel

Selective, novel spleen tyrosi ...... cell activation and migration.

@en

Selective, novel spleen tyrosi ...... cell activation and migration.

@nl

P1433

Q42221150-B290317A-88A3-4877-A96B-7738DEF55AC0

P1476

Q42221150-7ACCD8CB-3899-4847-B55E-33DE19054C86

P2093

Q42221150-01A62AAD-2CB1-4AC9-B0E8-1805EEE0A209

Q42221150-0913CD40-FA56-4923-9CE6-45CEC4670C65

Q42221150-23C6C1C9-303F-48FF-88B5-DAA130CB7A94

Q42221150-47EB1206-2B5B-48BD-A1B0-79C8E622D726

Q42221150-485F19DA-40F7-4285-BB8A-DF242E704235

Q42221150-54B9C0DC-A6DE-4E85-BE84-765F97249E39

Q42221150-553E0980-08E6-4661-9E46-997D4FCDD6DE

Q42221150-9F6AC4CB-F5C1-461C-9985-912BB5626187

Q42221150-B6C92310-FF42-41FE-9183-763040207A81

Q42221150-B9D142C3-B9D1-46B9-A0A5-EE79E30C49E0

P2860

Q42221150-0195CC89-9042-4556-B475-C814514BCA63

Q42221150-020DCB2F-2ACC-41F5-9A2A-5EFF953CF64E

Q42221150-0D6A0D37-596A-498E-A622-FDC35186C541

Q42221150-0E3EFA3C-8D93-4094-9106-5DAF316301B4

Q42221150-19C5A068-6C7E-4608-A11B-B174671BA7D5

Q42221150-1B032BC2-2384-49C0-8A59-D2D4E6C5A44E

Q42221150-26850443-127F-456F-ADCE-9EBB37331E1D

Q42221150-2B92358B-00A4-4A3B-AA46-EE76E92A2F53

Q42221150-2E2BE839-114A-45EC-B115-F45E990B2F92

Q42221150-487377A2-7338-4EFC-9D75-D6C56CD1B4D7

P2888

Q42221150-5940A7E6-1613-4F1F-8296-CD945399643C

P304

Q42221150-3B9C467C-2F0F-4D08-8E40-7EBAB424D435

P31

Q42221150-BA5C8FE1-55F8-40EA-BA8E-8A7C72266D50

P356

Q42221150-879D5B4D-76C6-4593-B014-A9442781CE19

P433

Q42221150-FE6FC06A-4974-4463-95C7-5EF301BFC1B5

P478

Q42221150-9418B346-D712-4C10-8609-7E27F2344AC1

P577

Q42221150-182C2CDA-0EB8-4A66-A235-5E110AC7E93C

P6179

Q42221150-FB2ED3F4-168A-4462-B3B1-8D9558661CD0

P698

Q42221150-FDC58F73-39E5-4503-A45B-C6CF0D7C2F7F

P921

Q42221150-2BC9163C-59A6-41BD-8048-2E832C0D7586

Q42221150-A4F5B036-BB8D-4F78-9C29-90B7D834AF7F

P932

Q42221150-A516983E-EAD9-4A7B-B8DE-3928B260E587

P356

P1433

P1476

Selective, novel spleen tyrosi ...... cell activation and migration.

@en

P2093

A Ferrajoli

http://www.w3.org/2001/XMLSchema#string

A Pandey

http://www.w3.org/2001/XMLSchema#string

F Ravandi

http://www.w3.org/2001/XMLSchema#string

G P Coffey

http://www.w3.org/2001/XMLSchema#string

J A Burger

http://www.w3.org/2001/XMLSchema#string

J Hoellenriegel

http://www.w3.org/2001/XMLSchema#string

M J Keating

http://www.w3.org/2001/XMLSchema#string

M Sivina

http://www.w3.org/2001/XMLSchema#string

S O'Brien

http://www.w3.org/2001/XMLSchema#string

U Sinha

http://www.w3.org/2001/XMLSchema#string

P2860

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

Chronic lymphocytic leukemia

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

P2888

P304

1576-1583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2012.24

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1022426422

http://www.w3.org/2001/XMLSchema#string

P698

22362000

http://www.w3.org/2001/XMLSchema#string

P921

P932

5459370

http://www.w3.org/2001/XMLSchema#string